Form 4: GeoVax Labs Executive Acquires Stock Options
SEC Form 4 Filing
Kelly T. McKee Jr., Chief Medical Officer of GeoVax Labs, Inc., reports the acquisition of stock options.
Summary
- On August 12, 2024, Kelly T. McKee Jr., the Chief Medical Officer of GeoVax Labs, Inc., acquired 15,700 stock options with an exercise price of $2.17.
- The options become exercisable in three equal annual installments starting on the first anniversary of the grant date.
- The expiration date for these options is August 12, 2034.
- Following this transaction, McKee directly owns 15,700 shares of common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to an executive.
Positives
- The acquisition of stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can influence investor sentiment.
Stakeholder Impact
- The acquisition of stock options by a key executive may influence investor confidence.
Key Dates
| Date | Description |
|---|---|
| 08/12/2024 | Date of stock option transaction |
| 08/12/2024 | Stock option grant date |
| 08/12/2034 | Stock option expiration date |
| 08/14/2024 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.